The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
Ferdinand
Keith C
KC
D001741:Black or African American / Q000235:genetics* / Q000706:statistics & numerical data; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004234:Diuretics, Osmotic / Q000627:therapeutic use*; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology / Q000627:therapeutic use*; D007548:Isosorbide Dinitrate / Q000494:pharmacology / Q000627:therapeutic use*; D019001:Nitric Oxide Synthase / Q000187:drug effects; D018570:Risk Assessment; D012959:Socioeconomic Factors; D014481:United States
D000959:Antihypertensive Agents; D004234:Diuretics, Osmotic; D004338:Drug Combinations; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D019001:Nitric Oxide Synthase; D007548:Isosorbide Dinitrate